Geneos Wealth Management’s Altimmune ALT Stock Holding History

Geneos Wealth Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.8K	Hold	10,000	–	–	﹤0.01%	1615
2025 Q4	$36.1K	Hold	10,000	–	–	﹤0.01%	1516
2025 Q3	$37.7K	Hold	10,000	–	–	﹤0.01%	1484
2025 Q2	$38.7K	Sell	10,000 -10,000	-50%	-$54.1K	﹤0.01%	1712
2025 Q1	$100K	Buy	+20,000	New	+$127K	﹤0.01%	1575
2020 Q4	–	Sell	-1,000	Closed	-$12K	–	2883
2020 Q3	$12K	Buy	+1,000	New	+$20K	﹤0.01%	1871

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geneos Wealth Management's ALT Position: Q1 2026 in Review

Geneos Wealth Management held its Altimmune (ALT) position steady in Q1 2026 at 10,000 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

Geneos Wealth Management first reported a position in ALT in Q3 2020 and has held it in 6 quarters since. The position peaked at $100K in Q1 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Geneos Wealth Management held 10,000 shares of Altimmune worth $30.8K as of Q1 2026.
Geneos Wealth Management left its Altimmune share count unchanged in Q1 2026.
Altimmune made up ﹤0.01% of Geneos Wealth Management's portfolio in Q1 2026, its #1615 holding.
Geneos Wealth Management first reported a position in Altimmune in Q3 2020 and has held it in 6 quarters since.
Geneos Wealth Management's Altimmune position peaked at $100K in Q1 2025.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.